Pfizer Inc. (PFE)
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
On Saturday, Pfizer Inc. PFE revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
Pfizer to pay $59.7 million over kickbacks for migraine drug
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT, the U.S. Department of Justice said on Friday.
Here's Why Pfizer (PFE) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Can This Beaten-Down Stock Bounce Back in 2025?
In 2022, pharmaceutical giant Pfizer (PFE -2.37%) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price.
Is Pfizer Stock a Buy?
Pharmaceutical giant Pfizer (PFE 1.29%) is trading near its lowest price in over a decade.
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $26.64, indicating a +1.29% shift from the previous trading day.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer CEO: Americans can expect radical change from this upcoming Trump administration
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S. president, becoming the second to serve two non-consecutive terms.
3 Upcoming Dividend Increases
This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of 8.7%. My strategy focuses on buying, holding, and adding companies that consistently increase dividends and outperform benchmarks. I use data from U.S. Dividend Champions and NASDAQ to guide my decisions. I prioritize stocks with strong historical performance and dividend growth, comparing them against benchmarks like SCHD and RNP for non-REITs and REITs, respectively.
What To Expect From PFE Stock In 2025?
Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), Pfizer's stock performance has been muted.
Why Pfizer sold its $3 billion stake in Haleon
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each, reduced Pfizer's ownership in the British consumer healthcare giant to 7.3%.
